300 filings
Page 4 of 15
8-K
be7vsb6yarnf3q491pc
9 Nov 21
Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
4:01pm
EFFECT
u0di5b
2 Nov 21
Notice of effectiveness
12:15am
424B3
epl1vh3l8w2b7voj
1 Nov 21
Prospectus supplement
4:10pm
CORRESP
ohbfncmafn
28 Oct 21
Correspondence with SEC
12:00am
CT ORDER
idofr
19 Oct 21
Confidential treatment order
12:00am
UPLOAD
32bw2j8b
15 Oct 21
Letter from SEC
12:00am
S-1
dvsamx78rgrc p8
8 Oct 21
IPO registration
4:14pm
8-K
h4ipfgnxp7isj7y
27 Sep 21
Entry into a Material Definitive Agreement
8:57am
8-K
j6fnd7ta9q5l8ixvmj4h
5 Aug 21
Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
4:16pm
8-K
uvupyu
30 Jul 21
Submission of Matters to a Vote of Security Holders
4:31pm
DEFA14A
edjf s8afv
16 Jul 21
Additional proxy soliciting materials
4:30pm
8-K
nqxs2jf
3 Jun 21
Entry into a Material Definitive Agreement
9:00am
8-K
prj1qir46 glw
25 May 21
Entry into a Material Definitive Agreement
5:10pm
424B5
wysme9h0eyftp
6 May 21
Prospectus supplement for primary offering
5:26pm
8-K
n4zxrq9
6 May 21
Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm